TCGA-IQ-A61I-01A-11R-A30B-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.000457
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.540
- E2F_TARGETS+0.350
- INTERFERON_ALPHA_RESPONSE+0.310
- DNA_REPAIR+0.270
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.250
- INTERFERON_GAMMA_RESPONSE+0.210
- ADIPOGENESIS+0.180
- FATTY_ACID_METABOLISM+0.180
- SPERMATOGENESIS+0.150
- ESTROGEN_RESPONSE_LATE+0.080
Top 10 suppressed
- TGF_BETA_SIGNALING-0.520
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.480
- UV_RESPONSE_DN-0.450
- HEDGEHOG_SIGNALING-0.390
- APICAL_JUNCTION-0.380
- PROTEIN_SECRETION-0.360
- UNFOLDED_PROTEIN_RESPONSE-0.340
- HYPOXIA-0.320
- WNT_BETA_CATENIN_SIGNALING-0.320
- ANDROGEN_RESPONSE-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CN-A6UY-01A-12R-A34R-07 | — | — | 0.922 |
| 2 | MDT-AP-2288 | Med | Medulloblastoma | 0.876 |
| 3 | TCGA-KU-A6H7-06A-21R-A31N-07 | — | — | 0.845 |
| 4 | TCGA-GV-A6ZA-01A-12R-A33J-07 | — | — | 0.824 |
| 5 | TCGA-P3-A5Q5-01A-11R-A28V-07 | — | — | 0.822 |
| 6 | 4245e942-3439-4e98-9733-b0b8ac25ad56 | — | — | 0.812 |
| 7 | SRR12475167 | — | — | 0.812 |
| 8 | c85dbfa4-b894-4ccb-9b90-94bb2c47cfea | — | — | 0.810 |
| 9 | TCGA-G2-AA3B-01A-11R-A39I-07 | — | — | 0.802 |
| 10 | TCGA-UP-A6WW-01A-12R-A34R-07 | — | — | 0.802 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.540 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.350 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.310 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.270 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.250 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.210 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.180 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.150 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.080 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.070 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.060 | Cobimetinib | — uncovered |
| NOTCH_SIGNALING | 0.050 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.020 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.020 | Temsirolimus | — uncovered |
| G2M_CHECKPOINT | 0.020 | Inavolisib | — uncovered |
| PEROXISOME | 0.020 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.020 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.010 | Inavolisib | — uncovered |